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Background: Chemotherapy-induced nausea and vomiting (CINV) are common adverse effects from chemotherapy.
While most treatments administered in patients with primary gliomas are not highly emetogenic, up to 50% of
neuro-oncology patients report CINV despite 5HT  or steroid therapies. Adjuvant benzodiazepines frequently alter
mental status. Dronabinol may provide a safe alternative option without compromise of neurological status. his
study seeks to describe toxicities (TOX) associated with dronabinol administration in neuro-oncology patients. A
secondary aim is to describe the impact that dronabinol has on their quality of life (QOL). Methods: This is an
exploratory study of adult patients with WHO Grade III/IV primary gliomas on adjuvant chemotherapy. Power
analysis determined a sample size of 34 subjects for 0.80 effect size. Enrollment is ongoing with 18/34 adult patients
accrued. Patients take dronabinol 5 mg BID 24 hours prior to, during, and 48 hours after completion of oral/IV
chemotherapy. Patients continue their established antiemetic regimen. Between chemotherapy doses, dronabinol is
reduced to 2.5 mg daily. Intolerance of dronabinol is defined as 2 or more Grade 3 or greater non-hematologic TOX
according to the CTC v.3 definition handbook. Modified Functional Living Index-Emesis (FLIE), Functional
Assessment of Cancer Therapy-Brain Tumor (FACT-Br), Mini Mental Status Exam (MMSE), and CINV visual analog
scales are collected at specific points for 2 cycles for TOX and QOL data. Results: Subjects are predominately male
(n=10); mean age of 45.2 years. Four withdrew due to Grade 3 neurologic TOX of cognitive changes (n=3) despite
decreasing dosages; Grade 3 persistent CINV (n=1) despite increasing dronabinol dosage. Increased dosages were
required in 4 subjects to better manage CINV. Two required decreased doses for Grade 2 neurologic TOX. Most
subjects (n=14) reported stable or improved QOL by FACT-Br and FLIE while the 4 withdrawn subjects reported
worsening QOL related to TOX. Conclusions: Dronabinol is safe and effective for administration as an adjunct to
standard antiemetic therapy during treatment for primary glioma. The dose may be titrated with minimal toxicities
and improvement in QOL.
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